Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Faeth Therapeutics, Inc.SNSE · Entity 5029 | Chief Business Officer | February 03, 2021 | February 05, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Faeth Therapeutics, Inc.
Report date February 03, 2021 · Filed February 05, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.00 · Expires 2031-02-02 | Direct | 83,333 |
Reported balance
After 2021-02-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-03 · Grant · Acquired 83,333 · Balance 83,333 F1: One-fourth (1/4th) of the options granted hereby shall vest and become exercisable on the first anniversary of the Vesting Commencement Date, February 3, 2021, thereafter one forty-eighth (1/48th) of the options granted shall vest and become exercisable each month following the Vesting Commencement Date, over four years such that the options shall be 100% vested on the fourth anniversary of the Vesting Commencement Date, subject to the grantee's Continuous Service (as defined in the 2021 Equity Incentive Plan) through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One-fourth (1/4th) of the options granted hereby shall vest and become exercisable on the first anniversary of the Vesting Commencement Date, February 3, 2021, thereafter one forty-eighth (1/48th) of the options granted shall vest and become exercisable each month following the Vesting Commencement Date, over four years such that the options shall be 100% vested on the fourth anniversary of the Vesting Commencement Date, subject to the grantee's Continuous Service (as defined in the 2021 Equity Incentive Plan) through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 03, 2021 Filed Feb 5, 2021 21:40 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantStock Option (Right to Buy) · Derivative | 83,333 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008090 · doc4.xml · derivative · entry 1 Hoey Anupama · CIK 0001843511 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,333 Underlying: Common Stock · 83,333 shares Expires 2031-02-02 F1 · derivative.exercise_date: One-fourth (1/4th) of the options granted hereby shall vest and become exercisable on the first anniversary of the Vesting Commencement Date, February 3, 2021, thereafter one forty-eighth (1/48th) of the options granted shall vest and become exercisable each month following the Vesting Commencement Date, over four years such that the options shall be 100% vested on the fourth anniversary of the Vesting Commencement Date, subject to the grantee's Continuous Service (as defined in the 2021 Equity Incentive Plan) through each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.